Rick E. Blakesley

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Cancer statistics, 2024

Cancer treatment and survivorship statistics, 2022

Bowel Disorders

Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions

Current approach to the treatment of chronic myeloid leukaemia

ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors

Gut microbiota modulation of chemotherapy efficacy and toxicity

Drug delivery systems for RNA therapeutics

Cancer-related inflammation and treatment effectiveness

Cancer Chemotherapy and Cardiac Arrhythmias: A Review

Cancer drugs and the heart: importance and management

2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

Cancer treatment and survivorship statistics, 2016

Cancer statistics, 2016

Cancer statistics, 2015

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

Cancer treatment and survivorship statistics, 2019

Cancer Drugs in the United States: Justum Pretium—The Just Price

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

Cardiovascular toxicity of biologic agents for cancer therapy.

Treatments for chronic myeloid leukemia: a qualitative systematic review

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (1234)

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.